Breath Actuated Nebulizer Study Protocol
Trial Snapshot
- Phase
- Not Applicable
- Status
- Withdrawn
- Locations
- 2
- Primary Endpoint
- Forced vital capacity
Study Overview
Brief Summary
Comparison of the researchers' standard nebulizer and a breath actuated nebulizer to examine if breathing medication can be delivered more quickly and as effectively or more effectively than the standard nebulizer.
Detailed Description
Background:
Generic nebulizers as well as breath actuated nebulizers have been available and FDA approved to administer therapy for years. Recently there has been interest in using breath actuated nebulizers to stream-line patient care in the hospital setting. Literature has found that breath actuated nebulizers are not only faster at delivering an equivalent dose, but more effective when measuring patient response to that therapy. There is no standard for method of converting from generic nebulizers to breath actuated technology.
Objectives:
We want to evaluate the use of Breath Actuated Nebulizer (BAN) technology versus generic nebulizers to improve quality of patient treatments and reduce nebulization duration to allow staff time to do complete patient assessments.
Inclusion Criteria:
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Single Group
- Primary Purpose
- Health Services Research
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Adult patients with orders for routine 2.5 mg albuterol sulfate nebulizer therapy ordered either Q4 or Q6 hours who consent to the study.
Exclusion Criteria
- •Adults with nebulizer therapy ordered more frequently than Q4 hours.
- •Adults with nebulizer therapy ordered less frequently than Q6 hours.
- •Pregnant patients are excluded.
- •Adults with orders for albuterol sulfate > 2.5 mg.
- •Adults in the ICU or Emergency Department.
Outcomes
Primary Outcomes
Forced vital capacity
Time Frame: 1
FEV1
Time Frame: 1
Secondary Outcomes
No secondary outcomes reported